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ABSTRACT
Introduction: Studies have shown that, at low
doses and with careful titration, combination
therapy with intrathecal ziconotide and
morphine results in rapid control of
opioid-refractory cancer pain. However, there
is a lack of published data regarding the efficacy
and safety of intrathecal ziconotide specifically
for the treatment of neuropathic cancer pain.
Case series: Case reports of ziconotide
intrathecal infusion in eight patients (age
45–71 years; 75% male) with chronic,
uncontrolled cancer pain during therapy with
intrathecal morphine plus bupivacaine were
reviewed. Neuropathic pain was confirmed in
five patients. Treatment was initiated with
adjunctive ziconotide when pain C5 on a
visual analog scale persisted in spite of 3
successive 20% dose increases of intrathecal
morphine. Ziconotide was initiated at
0.5–1.0 lg/day, with mean increases of 0.5 lg
every 4–7 days if required (maximum dose
10 lg/day; mean dose 4.9 lg/day). Pain
intensity was reduced in all patients after
3–5 days. Of the eight patients, three died for
reasons unrelated to ziconotide, three
discontinued treatment due to adverse effects
(predominantly psychoneurological disorders),
and one patient is still receiving treatment. One
patient discontinued ziconotide due to
confusion and delirium. Due to continued lack
of pain control with intrathecal morphine,
intrathecal fentanyl was initiated; however,
effective pain relief was not achieved with
1500 lg/day. Ziconotide was restarted and the
patient then achieved pain control.
Conclusion: On the basis of our clinical
experience, we recommend adding ziconotide
to intrathecal opioid-based therapy in cancer
patients with neuropathic pain inadequately
controlled by intrathecal morphine alone.
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INTRODUCTION
Cancer pain is a major health problem, affecting
up to 30% of patients with early-stage cancer,
and 65–85% of patients with advanced disease
[1–4]. Furthermore, at least one-third of patients
with cancer pain classify it as moderate or severe
[3, 5] and many patients do not receive
adequate pain management [6].
The neurophysiology of cancer pain is
complex and includes inflammatory,
neuropathic, ischemic, and compressive
mechanisms [7]. Pain in patients with cancer
can be caused directly by the cancer or can be
due to treatment or associated comorbidities.
Correctly identifying the underlying cause of the
pain will likely to lead to more appropriate pain
management strategies [8, 9]. This is particularly
important for neuropathic cancer pain, which is
more likely to be caused by treatment or
comorbid disease, and is more difficult to treat
than nociceptive cancer pain [8, 9].
Compared with the general population,
neuropathic pain has been studied in much
less detail in patients with cancer [9]. The
prevalence of neuropathic pain in patients
with cancer varies from 19% to 39.1%,
depending on whether or not patients with
mixed pain as well as pure neuropathic pain are
included in the definition [8]. Neuropathic
cancer pain is under-reported,
under-diagnosed, and under-treated, and other
treatment strategies are needed in addition to
opioid analgesia for optimal pain management
[8, 9]. Furthermore, the intrathecal
administration of drugs should be considered
in patients with chronic moderate-to-severe
pain when other less-invasive therapies fail or
if they produce intolerable adverse events
[10–12]. The intrathecally administered
non-opioid analgesic ziconotide, a
conopeptide that acts by selectively blocking
N-type calcium channels, is approved in the
United States in patients with severe chronic
pain that is refractory to other treatments [13],
and in Europe in patients with severe chronic
pain requiring intrathecal analgesia for pain
control [14]. Ziconotide can be used in
combination with other intrathecal drugs, and
there are studies that suggest that it has an
additive analgesic effect with opioids, with
minimal risk of developing dependence or
tolerance [15–23].
The 2012 Polyanalgesic Consensus
Conference (PACC) polyanalgesic algorithm
for intrathecal drug delivery in the
management of pain recommends ziconotide
as first-line intrathecal treatment options for
chronic refractory nociceptive, mixed, or
neuropathic pain [10]. Ziconotide is included
as a possible drug of choice for opioid
combination therapy in second- and third-line
treatments [10].
Numerous studies have demonstrated that
intrathecal ziconotide reduces the intensity of
pain in patients with and without cancer, albeit
with a high incidence of adverse effects [15,
17–23]. Recent studies have demonstrated that,
at low doses and with careful titration,
intrathecal combination therapy with
ziconotide and morphine resulted in rapid
control of opioid-refractory cancer pain [15,
16]. However, there is a lack of published data
regarding the efficacy and safety of intrathecal
ziconotide specifically for the treatment of
neuropathic cancer pain.
In this report, we present a case series
documenting the efficacy and safety of
intrathecal ziconotide added to intrathecal
morphine in eight patients with
opioid-refractory cancer pain, five of whom
had confirmed neuropathic pain.
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CASE SERIES
This retrospective case review included all
patients treated with intrathecal ziconotide for
neuropathic cancer pain at our pain unit
(Hospital Universitario Virgen del Rocı´o in
Seville, Spain) between 2009 and 2012. All
procedures followed were in accordance with
the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1964, as revised in
2013. Informed consent was obtained from all
patients included in the study.
At our pain unit, intrathecal ziconotide is
administered alone or in combination with
other drugs for all patients with
moderate-to-severe chronic pain who,
regardless of the cause of pain, do not show an
adequate response to other treatment regimens,
including intrathecal morphine, or who present
with significant adverse events to such
treatment. Patients with an estimated survival
time less than 3 months are eligible to receive a
completely implanted internal pump.
For this case series, neuropathic pain was
identified using the Spanish translation of the
Douleur Neuropathique (DN4) questionnaire [24].
The DN4 questionnaire consists of a total of 10
items:7 items related to the quality of pain
(burning, painful cold, electric shocks) and its
association with abnormal sensations (tingling,
pins and needles, numbness, itching), and three
related to neurological examination in the painful
area (touch hypoesthesia, pinprick hypoesthesia,
tactile allodynia). A score of one was given to each
positive item and a score of zero to each negative
item. The total score was calculated as the sum of
all 10 items, and the cutoff value for the diagnosis
of neuropathic pain was a total score of 4/10. A
visual analog scale (VAS), which ranged from 0
(no pain) to 10 (worst imaginable pain), was used
to assess pain intensity.
Between 2009 and 2012, we treated eight
patients with cancer pain using intrathecal
ziconotide (Table 1). The patients, aged
between 45 and 71 years, were predominantly
male (n = 6; 75%) and had uncontrolled pain, at
times with an intense neuropathic pain
component, during therapy with high doses of
intrathecal morphine plus bupivacaine
administered in conjunction with oral
adjuvant analgesic therapy, such as
amitriptyline, duloxetine, gabapentin, and
pregabalin. DN4 scores ranged from 2 to 10.
Five patients had a DN4 score C4, signifying a
diagnosis of neuropathic pain. Baseline VAS
scores ranged from 7 to 9.
Table 1 Baseline demographic and clinical characteristics of the eight patients who received treatment with ziconotide for
cancer pain at the Hospital Universitario Virgen del Rocı´o in Seville, Spain since 2009
Characteristic Patient number
1 2 3 4 5 6 7 8
Sex (M/F) M M F F M M M M
Age (years) 45 48 44 58 63 57 59 71
Cancer type Rectal Sciatic sarcoma Maxillary Rectal Colon Lung Prostate Laryngeal
DN4 score 5 10 4 8 4 2 3 3
VAS score 8 9 7 8 8 9 8 8
DN douleur neuropathique, F female, M male, VAS visual analog scale
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All patients received a fixed flux intrathecal
infusion pump (1 mL/day) with the catheter tip
positioned at the T6–T8 level. Treatment was
initiated with ziconotide when pain C5 on the
VAS persisted despite 3 successive 20 %
increases in the intrathecal dose of morphine.
The five patients with neuropathic pain did not
respond to high-dose intrathecal morphine
combined with bupivacaine. In all patients,
treatment with ziconotide was initiated at
0.5–1.0 lg/day (Table 2), with mean increases
of 0.5 lg every 4–7 days, depending on pain
control. Ziconotide was added to the intrathecal
therapy without discontinuing intrathecal
morphine. The maximum final dose of
intrathecal ziconotide was 10 lg/day, with the
mean final dose being 4.9 lg/day. Duration of
treatment ranged from 0.5 to 10 months.
A reduction in pain intensity was noted in all
patients 3–5 days after initiating treatment with
ziconotide. Compared with VAS scores of 7–9 at
baseline, patients had scores ranging from 3 to 6
at the end of treatment (Fig. 1). Of the eight
patients who received ziconotide, four died for
reasons unrelated to ziconotide treatment, three
required discontinuation of treatment due to
adverse effects, and one patient is still receiving
treatment.
Case 1
This 45-year-old male patient with metastatic
rectal cancer and neuropathic pain (DN4 score
of 5) was unresponsive to intrathecal morphine
12 mg/day (VAS score of 8). Intrathecal
ziconotide 0.5 lg/day was added to therapy in
April 2009. The patient was also receiving oral
gabapentin 900 mg every 8 h, amitriptyline
25 mg every 24 h, and transdermal fentanyl
200 lg. Intrathecal ziconotide was administered
for 10 months with no adverse events. At his
last assessment, the patient was receiving
ziconotide 10 lg/day plus morphine 12 lg/day,
and his VAS score was five. The patient died in
February 2010.
Case 2
This 48-year-old male patient had metastatic
sciatic sarcoma with neuropathic pain (DN4
score of 10). He was unresponsive to intrathecal
morphine 6 mg/day (VAS score of 9).
Intrathecal ziconotide 0.5 lg/day was added to
therapy in May 2009. The patient was also
receiving oral pregabalin 200 mg every 12 h,
amitriptyline 50 mg every 24 h, and
oxycodone/naloxone controlled release
Table 2 Intrathecal ziconotide and morphine combination therapy dosing information
Dosing Patient number
1 2 3 4 5 6 7 8
Ziconotide dose (lg/day)
Initial 0.5 0.5 0.5 0.6 1.0 0.5 0.5 0.5
Final 10 8 6 6 5 3.5 1 1
Morphine dose (mg/day)
Initial 12 6 10 8 9 11 12 15
Final 12 6 10 0 6 11 12 15
Ziconotide treatment duration (months) 10 8 7 3.5 2 2 0.5 1.2
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60/30 mg every 12 h. Ziconotide was
administered for 8 months with no adverse
events. At the patient’s assessment, his
ziconotide dose had been titrated to 8 lg/day,
and his morphine dose remained unchanged at
6 mg/day. The patient’s VAS score had
improved from 9 at baseline to five at the end
of treatment. The patient died in January 2010.
Case 3
This was a 44-year-old female patient with a
large maxillary tumor and neuropathic cancer
pain (DN4 score of 4). She was unresponsive to
intrathecal morphine 10 mg/day (VAS score of
7). Intrathecal ziconotide 0.5 lg/day was added
to therapy in June 2009. The patient was also
receiving oral gabapentin 900–1200 mg every
8 h, amitriptyline 25 mg every 24 h, and
oxycodone/naloxone controlled release
80/40 mg every 12 h. Ziconotide was
administered for seven months with no
reported adverse events. At the last assessment,
the ziconotide dose had been increased to
6 lg/day, and the morphine dose remained
unchanged. The VAS score had improved from
7 at baseline to 4 at the end of treatment. The
patient died in January 2010.
Case 4
This 58-year-old female patient with metastatic
rectal cancer and neuropathic pain (DN4 score
of 8) was unresponsive to intrathecal morphine
8 mg/day (VAS score of 8). She was also
receiving pregabalin 300 mg every 12 h,
amitriptyline 50 mg every 24 h, and
transdermal fentanyl 200 lg/h/day. Intrathecal
ziconotide 0.6 lg/day was added to therapy in
March 2010. The patient’s VAS score improved
50% from 8 at baseline to 4, but ziconotide was
discontinued after 3.5 months because the
patient developed a neuropsychiatric
disturbance that was considered to be related
to treatment. At the end of treatment, the
patient was receiving ziconotide 6 lg/day.
Intrathecal morphine was discontinued during
the 3.5-month treatment period.
Case 5
This 63-year-old male patient with locally
advanced colon cancer and neuropathic pain
(DN4 score of four) was unresponsive to
intrathecal morphine 9 mg/day (VAS score of
8). He was also receiving gabapentin 1200 mg
every 8 h, amitriptyline 50 mg every 24 h, and
transdermal fentanyl 250 lg/h/day. Intrathecal
ziconotide 1.0 lg/day was added to therapy in
August 2010. There was a two-point
improvement in VAS score, but ziconotide was
discontinued after 2 months of treatment (final
ziconotide dose 5 lg/day ? morphine
6 mg/day) due to confusion and delirium that
was considered to be related to treatment. The
patient then returned to intrathecal treatment
with morphine. Due to continued lack of pain
control at high doses of intrathecal morphine
Fig. 1 VAS scores of pain intensity at baseline and at the
end of treatment with intrathecal ziconotide. VAS visual
analog scale
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and poor tolerance of ziconotide, intrathecal
treatment with fentanyl was initiated. As
effective pain relief was not achieved after
reaching doses of fentanyl 1500 lg/day (VAS
score of 8), it was decided that treatment with
intrathecal ziconotide should be reinitiated.
Ziconotide was started at 0.7 lg and was
titrated to a final dose of 4 lg, at which time
the patient was also receiving intrathecal
fentanyl 1350 lg/day. The patient died in
August 2012, 6 months after improvement of
pain control was achieved with intrathecal
ziconotide and fentanyl (final VAS score of 6)
without adverse events requiring
discontinuation of the ziconotide infusion.
Case 6
This 57-year-old male patient with metastatic
lung cancer had a DN4 score of 2, indicating
that he had nociceptive rather than
neuropathic pain. He was unresponsive to
intrathecal morphine 11 mg/day, had a VAS
score of 9, and was also receiving oral
pregabalin 300 mg every 12 h, amitriptyline
50 mg every 24 h, and oxycodone/naloxone
controlled release 80/40 mg every 12 h.
Intrathecal ziconotide was added to therapy at
a starting dose of 0.5 lg/day. The patient’s VAS
score improved [50% from 9 at baseline to 4,
but ziconotide was discontinued after 2 months
(final ziconotide dose 3.5 lg/day ? morphine
11 mg/day) because the patient developed
confusion that was considered to be related to
treatment.
Case 7
This 59-year-old male patient with metastatic
prostate cancer had a DN4 score of three,
indicating that his pain was not primarily of
neuropathic origin. He had a VAS score of 8
during intrathecal therapy with morphine
12 mg/day. He was also receiving oral
gabapentin 900 mg every 8 h, duloxetine
60 mg every 24 h, and morphine
extended-release 100 mg every 12 h. The
patient began intrathecal ziconotide at a
starting dose of 0.5 lg/day, but treatment was
discontinued at 15 days (final ziconotide dose
1 lg/day ? morphine 12 mg/day) because of
adverse events (neurological and
gastrointestinal disorders) that were considered
to be treatment related. Final VAS score was 6.
Case 8
This 71-year-old male patient with metastatic
laryngeal cancer had DN4 score of three. He had
a VAS score of 8 during therapy with intrathecal
morphine 15 mg/day. He was also receiving
pregabalin 150 mg every 12 h, amitriptyline
25 mg every 24 h, and oxycodone/naloxone
controlled release 80/40 mg every 12 h.
Intrathecal ziconotide was started at a dose of
0.5 lg/day in July 2012, and the patient was
continuing treatment 1.2 months later with no
reported adverse events. At his last assessment,
the patient was receiving intrathecal ziconotide
1 lg/day and morphine 15 mg/day, and he had
a 62.5% in reduction in pain intensity (VAS
score of three).
DISCUSSION
The current case series suggests that addition of
intrathecal ziconotide to intrathecal morphine
therapy is a successful treatment strategy in
patients with cancer pain, including
neuropathic pain, refractory to high doses of
intrathecal morphine alone. Combination
therapy allowed rapid control of pain in our
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series of eight patients, as demonstrated by a
reduction in pain intensity as soon as three to
five days after the start of intrathecal
ziconotide. All eight patients, five of whom
had confirmed neuropathic pain, had a
substantial reduction in pain intensity of
C25%. Two of three patients with a C50 %
reduction in pain intensity had DN4 scores\4,
indicating that their pain was not primarily of
neuropathic origin, and the third patient
experienced effective relief of intense
morphine-refractory neuropathic pain.
To our knowledge, there are no other
published reports of the efficacy of an
intrathecal combination of ziconotide and
morphine in cancer patients with severe
neuropathic pain refractory to high doses of
intrathecal morphine. Two studies have
demonstrated the efficacy of intrathecal
combination therapy with ziconotide and
morphine in reducing pain that was
inadequately controlled by either intrathecal
morphine or ziconotide alone in patients with
chronic non-cancer pain [22, 25]. More recently,
intrathecal combination therapy with ziconotide
and morphine was shown to be a successful
treatment strategy in two studies of patients with
cancer pain refractory to high doses of oral
opioids [15, 16]. However, one of these studies
involved patients primarily with nociceptive
pain from bone metastases [15], and in the
other study results were reported only for the
study population as a whole, not specifically for
patients with neuropathic pain [16]. Our case
series therefore represents an important addition
to the small body of literature documenting the
efficacy of an intrathecal combination of
ziconotide and morphine in cancer patients
with severe opioid-refractory pain.
In addition to recommending ziconotide or
morphine alone as a first-line intrathecal
treatment option, the PACC considers the
combination of morphine plus bupivacaine an
option for first-line intrathecal therapy in
neuropathic pain [10]. There is a lack of data
on the use of ziconotide in combination with
other drugs [16]. However, as per the clinical
practice in our pain unit, there is sound
rationale for adding ziconotide to support the
effects of intrathecal morphine as part of a
multimodal intrathecal analgesia protocol [16,
22]. The PACC algorithms were created to help
guide clinicians in the safe and effective use of
intrathecal therapy, but physicians should use
their own best clinical judgment in making
treatment decisions for their patients [10]. Our
case series helps to demonstrate the
effectiveness of intrathecal combination
therapy with ziconotide and morphine in
cancer patients with neuropathic pain
refractory to first-line intrathecal
morphine-based therapy in clinical practice.
With respect to its safety profile, ziconotide
has a narrow therapeutic window, which
requires careful titration to determine the
lowest possible dose that is therapeutic and
sufficiently well tolerated. A high starting dose
and/or rapid dose titration can result in adverse
effects, including psychiatric abnormalities [12].
These events frequently require discontinuation
of ziconotide and are more likely associated
with rapid titration than with the final dose
achieved. Current PACC recommendations for
intrathecal ziconotide treatment highlight the
benefits of a slow titration plan to minimize the
risk of adverse events [10]. To reduce the risk of
serious adverse events, we employ a very low
starting dosage and a slow titration of
intrathecal ziconotide. However, it is necessary
to remember that we are dealing with patients
with relatively short-life expectancies, intense
and frequently increasing pain, and are under
significant social pressure for the rapid control
of pain. For all these reasons, we are often
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required to perform rapid titration of
ziconotide, with all the consequences that it
implies. In the patients documented in this case
series, treatment with ziconotide was initiated
at 0.5–1.0 lg/day (Table 2), with mean increases
of 0.5 lg every 4–7 days, while morphine dose
remained stable or was reduced. Four of the
eight patients discontinued intrathecal
ziconotide because of psychological/
neurological adverse events. One of these
patients was subsequently able to successfully
return to intrathecal therapy with ziconotide.
Ziconotide-related adverse events have
previously been reported with low doses of
ziconotide [16], and one of our patients
discontinued ziconotide because of adverse
events when receiving a very low 1 lg/day
dose. The other adverse events occurred in
patients receiving ziconotide 3.5–6 lg/day. The
maximum final ziconotide dose was 10 lg/day.
This dose was well tolerated with no reported
adverse events.
CONCLUSIONS
The use of combined intrathecal ziconotide and
morphine, together with the practice of slow
ziconotide titration, promotes successful pain
management in cancer patients with severe
refractory neuropathic pain. Although
ziconotide can be used as a first-line intrathecal
treatment option, on the basis of our clinical
experience, we recommend adding ziconotide to
intrathecal opioid-based therapy in cancer
patients with neuropathic pain inadequately
controlled by intrathecal morphine alone.
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